A Phase 3 interventional study of Bupivacaine 0.25% and Dexamethasone in Postoperative Pain and Total Hip Arthroplasty (THA), sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Assiut University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 148 studies testing dexamethasone in Pain, Postoperative — 27 open to participants now, 30 under way, 2 of them phase 3. Dexamethasone · Pain, Postoperative.
Among the 148 studies testing dexamethasone in Pain, Postoperative, this one is the 62nd largest by planned enrollment, is one of 17 that started in 2026, is one of 16 in phase 3, reaches primary completion later than 26 of the 29 other live ones, and was the 145th registered.
5,648 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.
Browse Pain, Postoperative studies →27 of the 148 studies testing dexamethasone in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:
Ain Shams University · Sites in Egypt
Ages 50–70
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19–79
Marmara University · Sites in Turkey
Ages 18–65 · Healthy volunteers
Beijing Tiantan Hospital · Sites in China
Ages 18–65
Oman Ministry of Health · Sites in Oman
Ages 21–80
By country, each count listing its studies:
Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
148 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 14 · Phase 3 19 · Phase 4 75
First in 2005; this study’s year is marked. 17 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 75 across 4,829 interventional studies indexed under Pain, Postoperative.
Median enrollment 89 across the 148 interventional studies. Of the 96 that completed or were terminated, 22 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 148 have an industry lead sponsor. The 10 most frequent:
Assiut University is the lead sponsor of 5,081 studies on the registry; 2,179 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
108 studies in Pain, Postoperative by Assiut University: 30 open now, 31 under way, 5 of them phase 3. Of 49 finished, 0 (0%) have results posted.
Among the 108 studies in Pain, Postoperative by Assiut University, this one is the 21st largest by planned enrollment of the 107 interventional ones that give a count, is one of 17 that started in 2026, is one of 5 in phase 3, reaches primary completion later than 17 of the 30 other live ones, and was the 101st registered.
Assiut University’s Pain, Postoperative studies by the year they started, since 2013.
11 of the studies testing dexamethasone in Pain, Postoperative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07413055Phase 3Oman Ministry of HealthComparative Efficacy Of 4 mg VS. 8 mg Submucosal Dexamethasone In Postoperative Pain Management After Dental Implant Surgery: A Randomized Double-Blind Controlled Clinical Trial | 2026-11-15 |
| NCT07847047Phase 3Assiut UniversitySafety and Efficacy of Dexamethasone Versus Dexmedetomidine as Adjuvants in PENG Block in Hip Surgeries for Postoperative Pain Management | 2027-10 |
| NCT07795281Gaziantep City HospitalIntravenous Dexamethasone Added to Dexmedetomidine After Superior Trunk Block | 2026-12 |
| NCT07380139Ain Shams UniversityDexamethasone vs Dexmedetomidine in Sphenopalatine Ganglion Block for Rhinoplasty Pain | 2026-12-01 |
| NCT07672873Marmara UniversityLocal Dexamethasone Administration in Symptomatic Irreversible Pulpitis | 2026-12-15 |
Add all 11 to your calendar (.ics) → With an account.
Among the 148 studies testing dexamethasone in Pain, Postoperative, from their registry updates:
Among Assiut University’s 108 in Pain, Postoperative:
This tab as a report to print or save as PDF → With an account.
This study evaluates and compares the analgesic efficacy and safety of adding dexamethasone versus dexmedetomidine to bupivacaine in an ultrasound-guided pericapsular nerve group (PENG) block combined with a lateral femoral cutaneous nerve (LFCN) block in patients undergoing elective total hip replacement under spinal anesthesia.
Total hip replacement is associated with substantial acute postoperative pain. The PENG block targets sensory articular branches supplying the hip while preserving quadriceps muscle strength, facilitating early postoperative ambulation. Supplementation with an LFCN block expands sensory coverage to the lateral surgical incision. Adding perineural adjuvants, such as dexamethasone or dexmedetomidine, to local anesthetics may prolong sensory block duration and reduce opioid requirements.
A total of 90 adult participants aged 18 to 60 years will be randomly assigned to one of three equal groups (30 patients each):
All participants across all groups will receive an LFCN block with 5 mL of plain bupivacaine 0.25% without adjuvants.
The primary outcome is the time to the first request for rescue analgesia (duration of postoperative analgesia). Secondary outcomes include total morphine consumption over the first 24 hours, pain intensity measured using the Visual Analogue Scale (VAS), intraoperative and postoperative hemodynamic stability, sedation levels, quality of recovery assessed at 24 hours via the Quality of Recovery-15 (QoR-15) questionnaire, and the incidence of any adverse effects or block-related complications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive an ultrasound-guided Pericapsular Nerve Group (PENG) block using 20 mL of plain bupivacaine 0.25% alone, followed by a lateral femoral cutaneous nerve (LFCN) block using 5 mL of plain bupivacaine 0.25% without adjuvant.
Drug: Bupivacaine 0.25%
Participants receive an ultrasound-guided Pericapsular Nerve Group (PENG) block using bupivacaine 0.25% with dexamethasone 4 mg added (total volume 20 mL), followed by an LFCN block using 5 mL of plain bupivacaine 0.25% without adjuvant.
Drug: Bupivacaine 0.25% · Drug: Dexamethasone
Participants receive an ultrasound-guided Pericapsular Nerve Group (PENG) block using bupivacaine 0.25% with dexmedetomidine 1 µg/kg added (total volume 20 mL), followed by an LFCN block using 5 mL of plain bupivacaine 0.25% without adjuvant.
Drug: Bupivacaine 0.25% · Drug: Dexmedetomidine
Plain bupivacaine 0.25% (20 mL) administered perineurally via ultrasound-guided Pericapsular Nerve Group (PENG) block, along with plain bupivacaine 0.25% (5 mL) for Lateral Femoral Cutaneous Nerve (LFCN) block without adjuvant.
Perineural dexamethasone 4 mg combined with bupivacaine 0.25% to an identical total volume of 20 mL, administered via ultrasound-guided Pericapsular Nerve Group (PENG) block, along with plain bupivacaine 0.25% (5 mL) for LFCN block.
Perineural dexmedetomidine 1 µg/kg combined with bupivacaine 0.25% to an identical total volume of 20 mL, administered via ultrasound-guided Pericapsular Nerve Group (PENG) block, along with plain bupivacaine 0.25% (5 mL) for LFCN block.
Time to First Request for Rescue Analgesia (Hours)
Duration of postoperative analgesia in hours, measured from the completion of the nerve block to the patient's first request for rescue analgesia (intravenous morphine PCA triggered for VAS score of 3 or greater). If a patient does not request analgesia within the observation period, data will be censored at 24 hours.
Time frame: Up to 24 hours postoperatively
No study locations are listed for this record.
Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.
Of 124 non-industry phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 12 months is below that.
Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dexamethasone · Dexmedetomidine